Table 1 Demographic and baseline characteristics
Variable | IABP n = 34 | CG n = 33 | p-value |
|---|---|---|---|
Gender, male | 27 (79.4%) | 24 (72.7%) | 0.520 |
Age, years | 64 ± 8 | 64 ± 10 | 0.750 |
LVEF (%) | 40 [36–42] | 40 [33–45] | 0.455 |
EuroSCORE | 6 [4–7] | 5 [3–6] | 0.158 |
Risk factors | |||
Previous cardiac surgery, n | 0 | 0 | – |
Previous myocardial infarction, n (%) | 31 (91.2%) | 24 (72.7%) | 0.049 |
Hypertension, n (%) | 26 (76.5%) | 27 (81.8%) | 0.427 |
Peripheral vascular disease, n (%) | 5 (14.7%) | 2 (6.1%) | 0.197 |
COPD, n (%) | 1 (2.9%) | 1 (3%) | 1.000 |
Current smoking, n (%) | 8 (23.5%) | 8 (24.2%) | 0.945 |
Previous smoking < 6 months, n (%) | 14 (41.2%) | 18 (54.5%) | 0.273 |
Dyslipidemia, n (%) | 19 (55.9%) | 27 (81.8%) | 0.022 |
Diabetes, n (%) | 16 (47.1%) | 17 (51.5%) | 0.715 |
Atrial fibrillation, n (%) | 3 (8.8%) | 2 (6.1%) | 1.000 |
Previous stroke, n (%) | 4 (11.8%) | 1 (3.0%) | 0.356 |
Hepatic disease, n (%) | 0 | 0 | – |
Obesity (BMI > 30) n (%) | 3 (8.8%) | 7 (21.2%) | 0.186 |
Left coronary trunk lesion > 50%, n (%) | 10 (29.4%) | 11 (33.3%) | 0.729 |
Valve disease, n (%) | 6 (17.6%) | 3 (9.1%) | 0.476 |
Medication | |||
Beta-blocker, n (%) | 25 (73.5%) | 29 (87.9%) | 0.138 |
ACE inhibitor, n (%) | 23 (67.6%) | 27 (81.8%) | 0.183 |
Acetylsalicylic acid, n (%) | 26 (76.5%) | 28 (84.8%) | 0.539 |
Vitamin K antagonist, n (%) | 1 (2.94%) | 2 (6.1%) | 0.614 |